drugset / Trial / NCT07554196
A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this study is to evaluate the safety of HH-101 antibody, administered as monotherapy to participants with advanced solid tumors.
Timeline
- Start
- 2022-01-19
- Primary completion
- 2023-08-09
- Completion
- 2024-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HH-101 | Protein / enzyme biologic | 0.3 mg/kg | Intravenous |
| Subject | HH-101 | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Subject | HH-101 | Protein / enzyme biologic | 3 mg/kg | Intravenous |
| Subject | HH-101 | Protein / enzyme biologic | 10 mg/kg | Intravenous |